Hanmi Science stock: Q3 sales rise as profit falls 51.3%

Published on 11/04/2026 at 01:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Hanmi Science stock saw third-quarter revenue rise while profitability weakened. Distribution growth supported sales during the July-September period.

Growth Meets a Steep Profit Decline

Third-quarter revenue increased as Hanmi Science expanded its pharmaceutical distribution business.
Operating profit and net income fell sharply during the July-September period.
The company operates as a healthcare holding group with pharmaceutical, medical-device, food and digital businesses.

Hanmi Science, KR7008930000, Illustration mit AI erstellt.

Hanmi Science reported stronger third-quarter revenue but sharply lower profitability on Tuesday, October 27, 2026. According to Yonhap News Agency, consolidated revenue rose 5.9 percent year over year to 362.9 billion won, while operating profit fell 51.3 percent to 19.2 billion won and net income dropped 51.1 percent to 15.6 billion won.

Distribution Supports Revenue

The July-September results show a clear split between sales growth and earnings. Hanmi Science said revenue from its pharmaceutical distribution subsidiary Online Pharm increased 7.3 percent year over year to 308.1 billion won, supporting the group top line.

The earnings decline leaves investors focused on the quality and durability of revenue growth. Rising distribution sales can expand scale, but the quarterly figures also show that higher sales did not translate into comparable operating or net-income growth.

Healthcare Portfolio Shapes Outlook

Hanmi Science is the holding company of the Hanmi healthcare group. Its business portfolio includes pharmaceutical distribution, medical devices, food, digital transformation and consumer healthcare platforms, while group companies cover drug development, pharmaceutical ingredients and pharmacy automation. The company also supports Hanmi Pharmaceutical's pipeline in oncology, obesity and diabetes, and rare and difficult-to-treat diseases.

Hanmi Science's corporate website describes a group structure centered on healthcare businesses in South Korea, China, Europe and Japan. That breadth gives the holding company exposure to both recurring distribution activity and longer-term pharmaceutical research and development.